Personalising Parkinson’s Drug Response
Parkinson’s disease is the second most common neurodegenerative disorder worldwide, and its incidence is rapidly rising In a significant breakthrough, researchers from Simon Fraser University (SFU) in Canada have uncovered why levodopa—the